| Phase 4 |
| NCT05882708 |
Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis |
Sepsis |
Recruiting |
2026-04-24 |
| Phase 3 |
| NCT06492395 |
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT |
Hepatocellular Carcinoma Non-resectable |
Recruiting |
2025-01-29 |
| NCT03949231 |
Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of… |
Liver Cancer |
Recruiting |
2024-06-26 |
| NCT05985798 |
Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC |
Hepatocellular Carcinoma Non-resectable |
Recruiting |
2023-08-14 |
| NCT05608200 |
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC |
Hepatocellular Carcinoma Non-resectable |
Recruiting |
2023-05-31 |
| NCT05608213 |
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC |
Hepatocellular Carcinoma Non-resectable |
Recruiting |
2022-11-08 |
| Phase 2/3 |
| NCT06478108 |
Interventional Software for Multi-immunotherapy of Solid Tumors |
Lung Cancer |
Recruiting |
2024-06-27 |
| NCT03952065 |
IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck… |
Head/Neck Neoplasm |
Recruiting |
2024-06-26 |
| NCT03755739 |
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for… |
Hepatocarcinoma |
Recruiting |
2024-06-25 |
| Phase 2 |
| NCT06904183 |
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT |
Hepatocellular Carcinoma Non-resectable |
Recruiting |
2026-08-11 |
| NCT06904196 |
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC |
Hepatocellular Carcinoma Non-resectable |
Recruiting |
2025-04-29 |
| NCT06397235 |
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC |
Hepatocellular Carcinoma Non-resectable |
Recruiting |
2025-02-20 |
| NCT06707233 |
Y-90 SIRT for Unresectable HCC Larger Than 7cm |
Hepatocellular Carcinoma Non-Resectable |
Recruiting |
2025-01-28 |
| NCT04770207 |
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs |
Hepatocellular Carcinoma |
Recruiting |
2024-08-21 |
| NCT06492408 |
Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma. |
Hepatic Cancer |
Recruiting |
2024-07-09 |
| NCT06492421 |
Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. |
Lung Cancer |
Recruiting |
2024-07-09 |
| NCT06483347 |
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT |
Lung Cancer |
Recruiting |
2024-07-03 |
| NCT06482801 |
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT |
Liver Cancer |
Recruiting |
2024-07-01 |
| NCT04803318 |
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced… |
Solid Tumor, Adult |
Recruiting |
2024-06-25 |
| NCT06397222 |
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC |
Hepatocellular Carcinoma Non-resectable |
Recruiting |
2024-05-07 |
| NCT07657273 |
Yttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular… |
Hepatocellular Carcinoma |
Not Yet Recruiting |
2026-06-18 |
| Phase 1/2 |
| NCT07374328 |
Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus |
Type 2 Diabetes |
Recruiting |
2026-01-28 |
| NCT03882840 |
Induced-T Cell Like NK Cellular Immunotherapy for Cancer Lack of MHC-I |
Anti-cancer Cell Immunotherapy |
Recruiting |
2024-06-26 |
| NCT05187338 |
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors |
Lung Cancer |
Recruiting |
2024-06-25 |
| NCT06480123 |
Stem Cell Derived Exome for Treatment of Diabetic Foot |
Diabetic Foot |
Not Yet Recruiting |
2024-06-28 |